185 related articles for article (PubMed ID: 16634808)
1. Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor.
Kameda H; Ishigami H; Suzuki M; Abe T; Takeuchi T
Clin Exp Immunol; 2006 May; 144(2):335-41. PubMed ID: 16634808
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.
Terabe F; Kitano M; Kawai M; Kuwahara Y; Hirano T; Arimitsu J; Hagihara K; Shima Y; Narazaki M; Tanaka T; Kawase I; Sano H; Ogata A
Mod Rheumatol; 2009; 19(5):522-9. PubMed ID: 19568828
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts.
Sandler C; Joutsiniemi S; Lindstedt KA; Juutilainen T; Kovanen PT; Eklund KK
Biochem Biophys Res Commun; 2006 Aug; 347(1):31-5. PubMed ID: 16806061
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
7. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A
Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591
[TBL] [Abstract][Full Text] [Related]
8. PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation.
Hirai T; Masaki T; Kuratsune M; Yorioka N; Kohno N
Clin Exp Immunol; 2006 May; 144(2):353-61. PubMed ID: 16634810
[TBL] [Abstract][Full Text] [Related]
9. Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes.
Rosengren S; Corr M; Boyle DL
Arthritis Res Ther; 2010; 12(2):R65. PubMed ID: 20380722
[TBL] [Abstract][Full Text] [Related]
10. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.
Paniagua RT; Chang A; Mariano MM; Stein EA; Wang Q; Lindstrom TM; Sharpe O; Roscow C; Ho PP; Lee DM; Robinson WH
Arthritis Res Ther; 2010; 12(1):R32. PubMed ID: 20181277
[TBL] [Abstract][Full Text] [Related]
11. The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast.
Migita K; Eguchi K; aoyagi T; Tsukada T; Tsuboi M; Kawabe Y; Nagataki S
Clin Exp Immunol; 1996 Apr; 104(1):86-91. PubMed ID: 8603539
[TBL] [Abstract][Full Text] [Related]
12. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
Paniagua RT; Sharpe O; Ho PP; Chan SM; Chang A; Higgins JP; Tomooka BH; Thomas FM; Song JJ; Goodman SB; Lee DM; Genovese MC; Utz PJ; Steinman L; Robinson WH
J Clin Invest; 2006 Oct; 116(10):2633-42. PubMed ID: 16981009
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells.
Li L; Blumenthal DK; Masaki T; Terry CM; Cheung AK
J Cell Biochem; 2006 Dec; 99(6):1553-63. PubMed ID: 16817200
[TBL] [Abstract][Full Text] [Related]
14. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
Abouantoun TJ; MacDonald TJ
Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
[TBL] [Abstract][Full Text] [Related]
15. Expression of platelet-derived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis.
Pohlers D; Huber R; Ukena B; Kinne RW
Arthritis Rheum; 2006 Mar; 54(3):788-94. PubMed ID: 16508943
[TBL] [Abstract][Full Text] [Related]
16. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
19. [Imatinib mesylate as a novel therapeutic drug for systemic rheumatic diseases].
Kameda H
Nihon Rinsho Meneki Gakkai Kaishi; 2007 Jun; 30(3):165-73. PubMed ID: 17603257
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
